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More than 90 capsular serotypes of Streptococcus pneumoniae coexist despite
competing for nasopharyngeal carriage and a gradient in fitness. The under-
lying mechanisms for this are poorly understood and make assessment of
the likely population impact of vaccination challenging. We use an individ-
ual-based simulation model to generalize widely used deterministic models
for pneumococcal competition and show that in these models short-term
serotype-specific and serotype non-specific immunity could constitute the
mechanism governing between-host competition and coexistence. We find
that non-specific immunity induces between-host competition and that sero-
type-specific immunity limits a type’s competitive advantage and allows
stable coexistence of multiple serotypes. Serotypes carried at low prevalence
show high variance in carriage levels, which would result in apparent out-
breaks if they were highly pathogenic. Vaccination against few serotypes can
lead to elimination of the vaccine types and induces replacement by others.
However, in simulations where the elimination of the targeted types is
achieved only by a combination of vaccine effects and the competitive pressure
of the non-vaccine types, a universal vaccine with similar-type-specific effec-
tiveness can fail to eliminate pneumococcal carriage and offers limited herd
immunity. Hence, if vaccine effects are insufficient to control the majority of
serotypes at the same time, then exploiting the competitive pressure by
selective vaccination can help control the most pathogenic serotypes.
1. Introduction
Streptococcus pneumoniae is a major global health problem [1], with an estimated
14 million serious cases of pneumococcal disease and 735 000 deaths annually
in young children [2]. It is also a major cause of morbidity and mortality in
adults, in both the developed and developing world alike. A perplexing feature
of pneumococcal ecology is the co-circulation of over 90 known capsular sero-
types despite their competition for the same ecological niche (the nasopharynx)
[3] and differences in the duration of carriage which pose an advantage for per-
sistence of some types [4]. With the introduction of conjugate vaccines that have
proved efficacious preventing nasopharyngeal colonization [5–7] to many
national vaccination schemes, this ecologic puzzle has become a public health
issue, as use of the first seven-valent pneumococcal conjugate vaccine (PCV7,
& 2013 The Authors. Published by the Royal Society under the terms of the Creative Commons Attribution
License http://creativecommons.org/licenses/by/3.0/, which permits unrestricted use, provided the original
author and source are credited.
targeted at the seven most prevalent serotypes among inva-
sive pneumococcal disease isolates in the USA) successfully
reduced carriage and disease related to these types, but
also resulted in replacement carriage and disease by non-vac-
cine types [8–14]. This replacement is thought to be an
inevitable effect of vaccinating against subpopulations of
pathogens which are competing with each other [3,15] and
has stimulated the development and use of higher valency
vaccines (PCV10, 13, 15 and a protein vaccine targeting all
serotypes).
With the rolling out of these newer higher valency vaccines
across the world [16,17], and the prospect of a valency arms-
race emerging, there is an urgent need to: (i) understand the
mechanisms that lead to competition between serotypes but
which also permits the coexistence of many types with varying
fitness, and (ii) be able to infer the likely population impact of
vaccination. Mathematical models have been used for these
purposes, but they have tended to model only two types and
have imposed between-host competition of serotypes as an
artificial factor reducing susceptibility against one serotype
while colonized with another [15,18]. These approaches are
likely to artificially increase coexistence [19], whereas those
that incorporate between-host competition in a more meaning-
ful way need both types to have a similar rate of secondary
infections for coexistence at population level to be possible [20].
The mechanism ensuring persistence of the variety of
pneumococcal serotypes in a competitive environment is lar-
gely unknown. A decreased likelihood of serotype-specific
colonization following acquisition of the respective serotype
(serotype-specific immunity) could support coexistence [21].
Data on natural acquired immunity against pneumococcal
carriage are sparse, but longitudinal carriage studies have
provided evidence for both serotype-specific and serotype
non-specific immunity following acquisition [22–25]. In
these, the probability for colonization with the homologous
or heterologous serotype respectively was found to be
reduced after previous colonization [22,23], suggesting exist-
ence of both a serotype non-specific immune response and a
serotype-specific immune response against acquisition of
pneumococcal colonization.
We use this information to generalize widely used determi-
nistic approaches and present a parsimonious mechanistic
model incorporating possible underlying means of immunity
induced by acquisition of colonization. The model is able
to reproduce many of the epidemiological and ecological fea-
tures of pneumococcus carriage, i.e. coexistence, competition,
epidemic and endemic patterns of disease, and serotype repla-
cement. Moreover, we use this model to assess the impact of
vaccination and show that high valency vaccines under some
circumstances may not be optimal.
2. Methods
We generalize deterministic approaches to the aspect of serotype
competition of the pneumococcus [15,18,26–28] by using an
individual-based model to describe the dynamics of up to 20
serotypes, which differ in their average duration of carriage. Full
details of the model are given in the electronic supplementary
material, appendix. In brief, acquisition of colonization induces
both a purely serotype-specific and a serotype non-specific
immune response. The duration of these and the duration of car-
riage are assumed to follow negative binomial distributions.
Immunity as considered in the model is fully protective directly
after acquisition and short-lived; the effect of repeated exposure
and maturation of the immune system is accounted for through
an exposure-independent and serotype non-specific decreasing
risk of transmission and carriage duration by age. To simulate
different fitness of serotypes, the mean duration of carriage in chil-
dren younger than 2 years of age was varied from eight weeks for
model serotype 1 to 3.25 weeks for model serotype 20 [29,30]. For
each serotype, independently, an individual can be in any of the
following four states: not colonized and susceptible; not colonized
and immune; colonized and susceptible; colonized and immune
(for a comparison with deterministic modelling approaches, see
the electronic supplementary material).
Data on two-way conversational contact patterns from a con-
tact survey, including the UK [31] were used to calculate
normalized age-specific contact rates for the age groups 0–1,
2–4, 5–9, 10–19, 20–39 and 40þ [32]. The risk of transmission
per contact was chosen to decrease by age in order to mirror
the decrease in prevalence with age in the UK [29] and to
cause the reproduction number (the average number of second-
ary colonizations caused by an average individual during the
course of carriage in a totally susceptible population, R0) to be
in the range of 1.1 to 2.7 for the different serotypes (low force
of infection (FOI) scenario), 2.2 to 5.4 (mid FOI scenario) or 4.4
to 10.9 (high FOI scenario).
We mainly considered two different vaccine scenarios: (i) a
vaccine providing immunity against the two most prevalent
types (bivalent vaccine), and (ii) a vaccine providing immunity
against all serotypes (universal vaccine). In both cases, one dose
of the vaccine was administered to children at two months of
age and offered a 65% chance for a 10 year protection against
the acquisition of any of the serotypes included in the respective
vaccine formulation [18,33–35]. We further investigate the merit
of the succession of the bivalent vaccine by the universal one
for which we allowed one additional infectious individual per
serotype to enter the population each month. The Cþþ model
code can be obtained from the corresponding author on request.
3. Results
(a) Competition and multiple carriage
The serotypes in the simulationmodel competewith each other
through colonization-induced immunity against acquisition of
all serotypes (non-specific immunity). After acquisition of a ser-
otype and during the infectious period, this leads to a reduced
pool of susceptibles available to other serotypes for onward
transmission; sowith increasing duration of non-specific immu-
nity, less serotypes can coexist within the host and hence in the
population owing to increasing competition (figure 1a,c).
(b) Coexistence
Coexistence of multiple serotypes in the simulated commu-
nity is conditional on the existence of serotype-specific
immunity. If serotypes limit their own transmission only to
the same extent that they limit the spread of competing sero-
types, then coexistence is unlikely; in fact, if serotype-specific
immunity is shorter than or equal to non-specific immunity,
then one serotype will dominate, and the others will be
driven to extinction. With increasing duration of serotype-
specific immunity, the numbers of serotypes stably coexisting
increases as type-specific immunity frees an ecological space
for other serotypes (figure 1a,b). Coexistence of multiple ser-
otypes within the host eases coexistence on population level
but, in the presence of serotype-specific immunity, is not
essential. The extent of multiple colonization of the hosts in
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the model is largely dependent on the duration of serotype
non-specific immunity. In particular, if the duration of
serotype non-specific immunity exceeds the duration of
carriage, then no additional colonization is possible, and a
short duration of non-specific immunity permits additional
acquisition before the colonising serotype is cleared.
(c) Variance of low prevalence serotypes
The variance of the standardized carriage prevalence increases
with decreasing prevalence levels, i.e. the serotypes at the verge
of extinction show high variance (figure 2). This finding is
robust to the model assumptions on immunity duration, the
FOI and the variance in duration of carriage (see the electronic
supplementary material, figure S2). The corresponding peaks
can stretch over multiple years. For those low prevalence types
that have a high propensity to cause invasive disease, this effect
would be amplified and picked up in the invasive pneumoccal
disease surveillance as an apparent epidemic of this serotype.
(d) Prevalence of carriage and the force of infection
Higher forces of infection generally lead to higher prevalence
of carriage. However, in the presence of between-host compe-
tition, this effect is marginal, as increasing the FOI in the model
leads to greater competition between serotypes, which acts to
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Figure 2. The variance of the serotypes’ standardized prevalence after the burn-in period (mid FOI scenario; mean-specific immunity duration: 18 weeks, mean non-
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Figure 1. The impact of specific immunity, non-specific immunity and carriage duration on serotype coexistence in the community and the proportion of multiple
carriage within the individuals. (a) The number of stably coexisting serotypes in the population (low FOI scenario) depending on the duration of non-specific and
specific immunity. The parameter space of high fractions of the population colonized with more than one serotype at a time is indicated by white solid lines. The
dashed line marks the space where at least 5% (at least one serotype, typically the most prevalent one) of all serotypes shows cyclic behaviour induced by
long duration of immunity. (b) Positive correlation of the number of coexisting serotypes and the mean duration of specific immunity for scenarios of a fixed
mean duration of non-specific immunity. (c) Negative correlation of the number of coexisting serotypes and the mean duration of non-specific immunity for scenarios
of a fixed mean duration of specific immunity. (Online version in colour.)
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counterbalance the effect of a higher FOI on prevalence
(see the electronic supplementary material, figure S3). A
more important factor determining the rate of colonization is
the duration of non-specific immunity. It is not, therefore,
possible to conclude which of the FOI scenarios is more
likely: indeed, it may well be that different settings are charac-
terized by very different epidemiologies.
(e) Vaccination
Introducing infant vaccination against the two most prevalent
serotypes into the model leads to extinction of these types in
both the vaccinated and, through herd immunity, the unvacci-
nated individuals. Replacement with non-vaccine types in
(figure 3) occurs according to the level of competition induced
by serotype non-specific immunity. Paradoxically, vaccination
against all serotypes—at the same efficacy and coverage—does
not necessarily cause extinction of all types in the unvaccinated
population and the benefits from indirect effects depend largely
on the associated FOI. Indeed, under the high FOI scenario, the
bivalent vaccine ismore effective at reducing adult carriage than
the universal vaccine. If the universal vaccine succeeds the biva-
lent one, re-emergence of previously controlled types can occur.
This effect arises, because the vaccine effects in the model are
insufficient to meet the herd immunity threshold and control
all serotypes simultaneously, in particular the more prevalent
ones,whereas for bivalent vaccinationvaccine serotypes are con-
trolled by a combination of vaccination effect which reduces the
number of transmission events by reducing the number of sus-
ceptibles and between-host competition from the non-vaccine
types (see the electronic supplementary material for further
details). When the competition is lessened, through the use of
a universal vaccine, and the effect of vaccination on its own is
not large enough to prevent effective transmission of all types,
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Figure 3. Equilibrium mean prevalence of different serotypes by age group (,10 years of age ¼ children, others ¼ adults) under different vaccination pro-
grammes: a bivalent vaccine targeting the two most prevalent types (VT1), and an universal vaccine (VT2) with the same efficacy per type. The duration of
non-specific and specific immunity was nine and 18 weeks, respectively. (Online version in colour.)
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these high prevalence (high R0) types can re-emerge (see the
electronic supplementary material, figure S6).
4. Discussion
We present here a parsimonious mechanistic model, devel-
oped as a generalization of existing deterministic models of
pneumococcal transmission, which is capable of reproducing
many of the distinct features of S. pneumoniae. We show that
the means of non-specific and specific immunity are capable
of governing the patterns of between-host competition and
coexistence, and that stochastic effects in low prevalent sero-
types may result in apparent epidemics, if these serotypes
also have a high propensity to cause invasive disease (as
has been observed in several countries with serotype 1, for
instance). We further show that high carriage prevalence
observed in developing country settings [25] and in native
populations [36] might arise from a less effective immune
response (owing to malnutrition, genetic differences or other
factors) rather than differences in the number of contacts
alone. Moreover, we use the model to assess the impact of
vaccination, and contrast a vaccine targeted at the most preva-
lent serotypes with a broad-based vaccine (e.g. a protein-
based one), with the same level of efficacy and coverage. Para-
doxically, we show that the low-valency vaccine can lead to
greater indirect effects (herd immunity), if the high prevalence
(most fit) serotypes are eliminated by a combination of vaccine
protection and between-host competition. This benefit over
the universal vaccine would be amplified in invasive pneumo-
coccal disease if the types included in the low-valency vaccine
are of high pathogenicity. Releasing the competition in the
model, by using a broad valency vaccine, can further lead
to a rebound in the previously controlled types.
The biological basis for protection against colonization and
clearance of carriage of S. pneumoniae is poorly understood.
However, from the patterns of pneumococcal acquisition of
colonization, clearance and re-acquisition found in longitudinal
carriage studies conducted over 1 and 2 years, respectively, the
existence of serotype-specific and non-specific protection can be
inferred [22,23]. This is reflected in the model as a short-term
fully protective immunity to acquisition of colonization. With
these two mechanisms, we were able to generate the specific
ecological and epidemiological patterns of the pneumococcus.
Short-term specific and non-specific protection might arise
from a combination of both the innate and the adaptive
immune response. While an activated innate response which
is associated with increased macrophage or other myelomono-
cytic cellular activity might limit initial growth of the
pneumococcus in the mucosa, the innate response is short-
lived and unlikely to be the main effector for clearance of
pneumococcal colonization which may persist for prolonged
periods (up to five months) before clearance [37]. However,
the innate response probably has the role of activating an adap-
tive immune response that develops to both serotype-specific
capsule and conserved surface proteins that produce cross-
reactive antibodies. These responses could be mediated by
locally produced antibody from mucosal B cells which persist
after the pneumococcus has been cleared and prevent initial
growth or enhance clearance in the event of a subsequent heter-
ologous exposure (via non-specific antibody) or homologous
exposure (both non-specific and serotype-specific antibody).
Although essential in murine models, the role of T-cells in
clearance in the human isyet unclear [38,39].Wedid not include
a mechanism in the model to track colonization events over an
individuals’ lifetime to infer long-term immunity which could
bemediated by both capsule-specific and non-specific antigens,
but chose to only include its observed effects; a serotype non-
specific decline in carriage duration and the probability for
transmission given contact by age. Including long-term immu-
nity induced via past history of exposure together with a
general maturation of the immune system would increase the
realism of the model, but cannot be realized in a deterministic
approach on which we build here.
Serotype non-specific immunity in the simulation model
acts to reduce the window of opportunity for other serotypes
to colonize the host and hence reduces acquisition rates.
This mechanism is supported by various studies [23,27,40].
Non-specific immunity and hence competition between the ser-
otypes could also act through increased clearance rates.
However, while a general decrease in the duration of carriage
by age has been identified [18,41], this could not be associated
directly with exposure to the pneumococcus [27] and was
reflected as such in this model. We chose a mostly data-free
approach and explored the effect of various parameter assump-
tions on simulated rates of coexistence, carriage oscillatory
patterns and multiple carriage (see the electronic supplemen-
tary material, figure S4). Most scenarios presented assumed
the duration of non-specific immunity to be nine weeks. This
was chosen on the basis of the rate of multiple carriage being
found to be very low using current standard detectionmethods
[8,42–45]. However, recently developed and yet to be estab-
lished methods yield higher rates of multiple carriage [46]. If
one accounts for that, then onewould need to decrease the dur-
ation of non-specific immunity in the simulations, whichwould
further increase the likelihood of serotype coexistence.
Other models have studied between-host competition
between serotypes typically using competition as a factor
limiting the FOI for additional acquisition once colonized
in a deterministic two strain model [15,18,27]. While providing
a useful tool to estimate the degree of competition and thereby
inferring the possible effects of vaccination [47], questions
about model validity in the absence of an explicit underlying
mechanism have been raised [19,20]. We show that the
parameter choice ensuring coexistence (serotype-specific
immunity being longer than serotype non-specific immunity)
in this model provides a close match to the deterministic
approach most frequently used for modelling competition
of two types (see the electronic supplementary material,
appendix: model 4). The role of short-lived strain-transcending
immunity has been previously identified to be an important
determinant of the ecology of influenza by restricting the
strain diversity [48]. Similarly, Zhang et al. [26] identified
direct competition through physical presence or activated
innate immune response as the most likely source of compe-
tition of the pneumococcal serotypes. In our approach, short-
lived non-capsule-specific immunity induces competition
and hence limits strain diversity within the host and on popu-
lation level. However, we find that serotype-specific protection
can counterbalance this limiting factor and lead to the vast
diversity of pneumococcal serotypes.
Recently, Cobey & Lipsitch [21] published that the means
of serotype-specific and serotype non-specific immunity can
account for the observed diversity of the pneumococci,
which supports the conclusion we reach here. In their
work, serotype-specific immunity is represented as partially
rspb.royalsocietypublishing.org
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protective lifelong serotype-specific reduced susceptibility to
carriage acquisition induced by the first clearance of coloniza-
tion and an exposure driven reduction in carriage duration.
The authors consider serotype non-specific immunity to be
short-lived and partially protective, in particular the suscep-
tibility for acquisition of another serotype is reduced during
carriage according to the fitness rank of the most fit serotype
currently carried. Similar to Cobey and Lipsitch, we do con-
sider non-specific immunity short-lived, however fully
protective (see the electronic supplementary material for
details), and do not include a possible direct impact of immu-
nity on reducing infectiousness, only indirectly through
reduction of carriage duration. By contrast, we assume sero-
type-specific immunity to be short-lived rather than lifelong
and partially protective, and attribute the reduction in dur-
ation of carriage to serotype non-specific effects by age and
not exposure related. While there is evidence supporting
both their approach and the one presented here, in the absence
of established correlates of protection against pneumococcal
carriage neither of the approaches can be overwhelmingly
favoured. However, despite those differences in design, both
approaches are able to reproduce observed patterns of carriage
prevalence and multiple carriage as well as serotype replace-
ment following selective vaccination, and similar conclusions
are reached. Cobey and Lipsitch’s work supports our finding
that serotype-specific immunity may be the main driver for
the coexistence of serotypes and that stochastic effects alone
can account for apparent epidemics of serotypes carried at
low levels and with high pathogenicity. We add to this the dis-
cussion of our approach in the context of the feasibility and
possible underlying assumptions of deterministic modelling
approaches and their issue of neutrality, where we find that
serotype-specific immunity as modelled here could be the
underlying mechanism required to ensure serotype coexistence
in the model of Lipsitch [15], and also to be responsible for its
non-neutrality [19]. We further explored the impact of compe-
tition on vaccination contrasting vaccines with different
valencies and found that exploiting competition by selective
vaccination can help with the control of some serotypes
where vaccination would fail the herd immunity threshold
in the absence of competition.
Long-term temporal trends and cycles have been
observed in some serotypes via the surveillance of invasive
pneumococcal disease. Assuming that the pathogenicity of
the serotypes is unchanged, the source of these trends has
to be the changing abundance of these serotypes in nasophar-
yngeal carriage. Interestingly, this observation has been
mostly confined to infrequently carried serotypes, in particu-
lar serotype 1 [11,49,50] and has made the interpretation of
the epidemiology of the pneumococcus challenging. If not
accounted for, then outbreaks of highly pathogenic serotypes
can substantially distort the analysis of vaccine effects, as
such analyses generally attribute all changes in epidemiology
to the introduction of the vaccine. For example, this was
recently observed in the UK [11,51] where vaccine introduc-
tion coincided with a change in serotype 1 epidemiology.
In our simulation model, we study one potential cause of
this occurrence: long duration of serotype-specific immunity
causes cyclic prevalence patterns with regularly occurring
pronounced peaks (see the electronic supplementary
material). However, this effect is most pronounced in more
frequently carried types rather than the low prevalence
types. Hence, to reproduce the cyclic trends being restricted
to mainly low prevalence serotypes, these serotypes would
need to induce a considerably longer capsule-specific protec-
tion compared with the more frequently carried serotypes.
Similar to Cobey and Lipsitch, we find an additional poten-
tial cause of this epidemiologic occurrence which might
interact with or amplify trends owing to serotype-specific
immunity: infrequently carried serotypes are most prone to
high variance in standardized prevalence solely owing to sto-
chastic effects. Although the outbreak size can differ
depending on various factors, including population size,
inter-serotype differences in carriage duration and infection
pressure, we consistently find that stochastic effects alone
can lead to substantial differences in the prevalence for
those types which are carried stably but at the verge of extinc-
tion (compare the electronic supplementary material, figure
S2). This can result in peaks which spread over several
years. If these low carriage prevalence but high variance ser-
otypes are highly pathogenic (as is the case with serotype 1
[8]), then these hardly notable peaks in carriage prevalence
will be amplified and picked up by surveillance systems
which mainly monitor invasive pneumococcal disease.
Vaccination in the model framework with a bivalent vac-
cine formulation consisting of the two most prevalent
serotypes and an efficacy of 65% led to extinction of the tar-
geted types in all scenarios tested. However, the effect on
overall carriage was marginal owing to serotype replacement
by the untargeted types. No significant overall decline has
been observed in most nasopharyngeal carriage studies asses-
sing the impact of vaccination with the PCV7 [8,9], however,
some did [43,52]. This apparent difference to our model
could be due to various reasons, including the lack of power
in most studies to detect this rather small decline. Although
the effect on carriage was marginal, the introduction of
PCV7 to national childhood vaccination programmes around
the world led to substantial reduction in invasive disease,
because it targeted mainly highly pathogenic serotypes.
PCV10 and PCV13 are thought to have a similar effect [8].
The results on potential outcomes of vaccines with high
valency presented in this manuscript are based on a highly
simplified representation of pneumococcal transmission,
where important aspects of pneumococcal transmission are
missing, including the exclusion of partially protective immu-
nity and reduced transmissibility as a function of previous
exposure, which neglects a possible shift in carriage ranks in
older age groups. A further limitation is the assumption of
the model that immunity against carriage acquisition induced
by vaccination is substantially longer lasting than the serotype-
specific short-term immunity induced by colonization,
although there is no evidence from the design of the vaccine
that there should be any difference. Existing deterministic
approaches implicitly make similar assumptions. Here, a
model formulation of longer lasting but partially protective
serotype-specific immunity could prove superior and might
lead to different outcomes. Hence, our results regarding vacci-
nation cannot be interpreted as forecasts. Rather these results
illustrate a potential structural disadvantage of high valency
vaccines over vaccines which only target specific pneumococ-
cal serotypes: the loss of competitive effects induced by
non-vaccine serotypes which act to further limit the trans-
mission of the vaccine serotypes. The magnitude of this
disadvantage and the associated effects are conditional on
many aspects, including the strength of competition, the trans-
missibility of the serotypes and the vaccine effectiveness
rspb.royalsocietypublishing.org
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(including level of protection against carriage, coverage levels
and the duration of protection), and will need to be verified in
other model structures and ideally real-world scenarios. In
particular, a perfectly efficacious vaccine, delivered at high
coverage levels and inducing long-lasting protection is likely
to eliminate transmission of all targeted serotypes, irrespective
of the pneumococcus’ transmissibility and competition. How-
ever, our results suggest that a universal vaccine with similar
type-specific effectiveness to the bivalent one, which is set to
mirror observed vaccine effects of PCV7, may fail to eliminate
pneumococcal carriage and offer limited herd immunity,
because the beneficial effect of competition between types is
lost. Hence, the indirect effects of high valency vaccination
should be studied in detail before introduction of the vaccine
to avoid possible adverse effects. These results also mean
that—contrary to conventional wisdom—pursuing ever
wider serotype coverage (by the use of a protein-based vac-
cine, for instance) may not necessarily yield increased public
health benefits. Alternatively, vaccine formulations that only
include those serotypes with the highest likelihood of severe
disease given colonization could be an effective way to
reduce the burden of disease while only causing minor disrup-
tions to pneumococcal ecology and hence a limited probability
of causing adverse effects.
The concept of pathogens competing for the same ecologi-
cal niche and the implications for vaccine programmes might
be applicable to other settings too. For example, quadrivalent
meningococcal vaccines including the frequently carried but
relatively unpathogenic serogroup Y are at risk for reducing
potential competitive pressure to other serogroups, in particu-
lar serogroup B. Whether these vaccines will affect the
prevalence of either the other MenB strains or other meningo-
coccal serogroups remains to be seen. Inter-species competition
has also been reported. Reduced carriage of Staphylococcus
aureus in individuals colonized with the pneumococcus has
been detected, suggesting that there may be an increase of S.
aureus after introduction of the PCV [53–55].
We present a structurally simple model that includes
serotype-specific and non-specific immunity. We find that
this mechanism, which is likely to be a combination of the
innate and the adaptive immune response, is sufficient to
grant the key epidemiological features of the pneumococcus:
coexistence, between-host competition and multiple carriage,
and leads to the emergence of possible epidemic strains, as
well as serotype replacement following vaccination. Further-
more, we illustrate the effect of competition on vaccination
and show that selective vaccination can possibly exploit com-
petition to enhance vaccine effects on specific serotypes
where vaccine effects alone would not be sufficient to control
transmission via herd immunity effects.
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